DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...

Fintel reports that on March 10, 2025, Lake Street downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.